Viewing StudyNCT01524926

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 12:15 AM
Last Modification Date: 2024-10-26 @ 10:46 AM
Study NCT ID: NCT01524926
Status: COMPLETED
Last Update Posted: 2023-12-11
First Post: 2012-01-24
Brief Title: CREATE Cross-tumoral Phase 2 With Crizotinib
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Organization: European Organisation for Research and Treatment of Cancer - EORTC
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Locally Advanced andor Metastatic Alveolar Rhabdomyosarcoma
Locally Advanced andor Metastatic Anaplastic Large Cell Lymphoma
Locally Advanced andor Metastatic Inflammatory Myofibroblastic Tumor
Locally Advanced andor Metastatic Papillary Renal Cell Carcinoma Type 1
Locally Advanced andor Metastatic Alveolar Soft Part Sarcoma
Locally Advanced andor Metastatic Clear Cell Sarcoma
Keywords:
Name View
Alveolar rhabdomyosarcoma View
Phase 2 View
Crizotinib View
Anaplastic large cell lymphoma View
Inflammatory myofibroblastic tumor View
Papillary renal cell carcinoma type 1 View
Alveolar soft part sarcoma View
Clear cell sarcoma View